Cytosurge elects veteran biotech executive, investor, and company builder Luba Greenwood, J.D., to its Board of DirectorsLuba Greenwood joins Cytosurge’s Board of Directors to support the company’s next phase of commercial growth and scientific progress as Cytosurge builds the causal data foundation for AI-driven drug discovery.
Cytosurge’s CellEDIT Conquers "Impossible" Genome Engineering ChallengesA new peer-reviewed study validates CellEDIT’s ability to overcome cell-editing barriers, uncovering dermokine’s pivotal role in wound healing and skin cancer biology.
Cytosurge Appoints Magid Haddouchi as Chief Commercial OfficerNew CCO Joins as Cytosurge Engages in Key Scientific Events Across the USA and Beyond
Cytosurge Announces Strategic Leadership TransitionSimon Egli Appointed Chief Executive Officer as Co-Founder Pascal Behr Transitions to Board of Directors
Cytosurge's CellEDIT Workflow, based on its Proprietary FluidFM® Technology, Receives Validation in Peer-Reviewed PublicationGLATTBRUGG, Switzerland, May 29, 2024 (GLOBE NEWSWIRE) -- Cytosurge AG, a biotech company pioneering innovative single-cell biopsies and cell engineering solutions, today announced the open-access publication of its CellEDIT workflow in the peer-reviewed journal Biotechnology Journal. Titled “Accelerated generation of gene-engineered monoclonal CHO cell lines using FluidFM nanoinjection and CRISPR/Cas9”, the manuscript introduces CellEDIT as a novel approach to cell engineering that leverages intranuclear delivery of CRISPR components to single cells through Cytosurge's proprietary FluidFM® OMNIUM Platform technology.
